Vertex Pharmaceuticals (VRTX) Q3 2026 Earnings Call: Q&A Summary

Q: Cory Kasimov from Evercore asked about the recent citizen petition regarding Ranir's IgG monitoring and dose hold rules, how frequently patients fall below thresholds, and monitoring requirements in the commercial label.

A: Reshma Kewalramani, CEO and President, responded that anonymous petitions are common and that FDA interactions are proceeding normally. She noted that clinical trials over 500 people monitored IgG every 4 weeks and that severe adverse events of infection were balanced at 0.5% in pove versus placebo with no opportunistic infections.

Q: Jessica Fye from JPMorgan asked what would represent a win in the amplitude interim analysis regarding proteinuria and eGFR.

A: Reshma Kewalramani, CEO and President, stated that while proteinuria is measured, the accelerated approval agreement with the FDA is based on a statistically significant difference in eGFR slope between the anaxaplin-treated group and placebo on top of standard of care.

Q: Salveen Richter from Goldman Sachs asked about comfort with Pove manufacturing and the reasons for confidence in the anaxiplen 48-week interim data.

A: Reshma Kewalramani, CEO and President, stated they have used the same manufacturer throughout Phase III, with CMC review underway, and expressed confidence in the interim anaxiplen data based on established links between substantial proteinuria reductions and eGFR improvements in homogeneous proteinuric kidney diseases.

Q: Geoffrey Meacham from Citibank asked how much the 2-year eGFR data for Pove will impact competitive positioning and what a win looks like for the DPN pain trials.

A: Reshma Kewalramani, CEO and President, explained that completing the 2-year eGFR study supports global filings where regulators require 2 years, and for DPN, a win is defined as susetrigene beating placebo to enable regulatory approval.

Q: Evan Seigerman from BMO Capital Markets asked about the bridge between prescription growth and reported revenue as the patient support program rolls off in mid-2027.

A: Duncan McKechnie, Chief Commercial Officer, stated that keeping the patient support program active helps patients whose plans do not yet cover the drug, and upon sunsetting it in mid-2027, gross-to-net is expected to stabilize at 50% to 60% with commensurate revenue growth.

Q: Brian Abrahams from RBC Capital Markets asked how initial Pove uptake balances against existing class therapies and what drives ALYFTREK conversion.

A: Duncan McKechnie, Chief Commercial Officer, noted that ALYFTREK growth is driven by new reimbursement agreements and rare mutation label expansions, while for Pove, the vast majority of the 163,000 untreated patients remain available alongside strong nephrologist enthusiasm for early treatment.

Q: Michael Yee from UBS asked about eGFR delta expectations for anaxiplen relative to IgAN data and whether the Parasol working group influenced proteinuria endpoints.

A: Reshma Kewalramani, CEO and President, noted that targeting the underlying cause via upstream APRIL BAFF inhibition yields beneficial eGFR impacts, and while the Parasol community explores proteinuria endpoints for AMKD, Vertex's agreement with the FDA remains anchored on GFR.

Q: Tazeen Ahmad from Bank of America asked how 828 data compared to preclinical expectations and where the biggest remaining unmet need is in CF.

A: Reshma Kewalramani, CEO and President, stated that 828 achieved strong sweat chloride reductions over 28 days compared to TRIKAFTA, but Vertex will review data across all three next-gen 3.0 family molecules before deciding on pivotal development, aiming eventually for fully normal sweat chloride distributions.

Q: Akash Tewari from Jefferies asked why the decision to pursue 2-year eGFR data was made now and how dropouts are handled statistically.

A: Reshma Kewalramani, CEO and President, explained that continuing to 2 years supports global filings outside the U.S. where regulators require 2-year data, and missing data is managed according to clearly established statistical analysis plan rules.

Q: Terence Flynn from Morgan Stanley asked whether a small subset of FSGS patients drove the proteinuria reduction in the moderate proteinuria cohort of AMPLIFIED.

A: Reshma Kewalramani, CEO and President, confirmed that the majority of patients in cohort 1 did not have FSGS, so the response was not driven by an FSGS subset.

Q: Mohit Bansal from Wells Fargo asked if continuous manufacturing used for Pove raises any concerns or if FDA involvement has been sufficient.

A: Reshma Kewalramani, CEO and President, confirmed that the FDA has been fully involved throughout the review process, including the complete CMC and manufacturing module submitted in March, and management feels very good about the filing.